Pfizer Stock: Still Cheap Valuation Meets A Looming Patent Cliff (NYSE:PFE)
· seekingalpha.com
Pfizer reported second quarter results, and the company did beat analysts’ estimates for revenue as well as earnings per share. Read why PFE stock is a buy.
In previous articles I certainly didn't see Pfizer Inc. ( PFE ) as the best investment one can make. The company is facing a massive patent cliff. But I was sti...